Search is Powered by Google
Cancer / Oncology News

'Point Of Care Diagnostics' In The Starting Blocks

Main Category: Cancer / Oncology
Article Date: 19 Aug 2008 - 2:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Tracking down cancer at a very early stage, studying cell growth, developing new medicines: future lab-on-a-chip systems will use nanoscale electrical fields to enable the detection and manipulation of cells and biomolecules. The University of Twente's eLab4Life project can expect a grant of 2.4 million euros from the European Research Council for this research.

Lab-on-a-chip systems bring the laboratory to the patient instead of the other way around: a blood sample will no longer have to go to the laboratory and the patient will no longer have to wait for the result; a pocket-sized laboratory that gives the result on the spot will soon be available. This is called 'point-of-care diagnostics'. According to Prof. Albert van den Berg, who leads the University of Twente's BIOS Lab-on-a-chip group, a real breakthrough can be expected from making special nanoscale structures for generating electrical fields that can be used to study individual cells or molecules: "So far a lot of experiments have been carried out with optical techniques that are sometimes difficult to integrate in a complete system. The new nanostructures we envisage will make it possible for us to miniaturize systems even further and to develop commercially-feasible equipment."

Precise control

Amongst other things, he anticipates that this research will provide opportunities for developing extremely sensitive chips that can detect biomarkers for cancer at a very early stage, and thus enable better treatment. Van Den Berg also wants to study cell growth on the new chips. The advantage of miniaturization here is that the environment in which the cell grows can be controlled very precisely. This precision is a great advantage for the development of new medicines, too: the researchers want, for example, to allow two types of cells to fuse on a chip to form new cells that will produce medicines.

Spin-off

Van den Berg's group, a unit of the MESA+ Institute for Nanotechnology, has built up a global reputation in this field. A chip has, for instance, already been developed that realizes point-of-care diagnostics for people who use the medicine lithium. The spin-off enterprise MediMate will be launching this development on the market in the near future. In the eLab4Life project the group will be working together with Prof. Jurriaan Huskens' Molecular Nanofabrication group and Prof. Clemens van Blitterswijk's Tissue Regeneration group.

The European Research Council's Advanced Grants are European subsidies for research that opens up new horizons. One hundred and five of almost a thousand applications in the field of Physical Sciences and Engineering have been awarded one of these grants. Nine of these winning projects are based in the Netherlands. Albert van den Berg's eLab4Life project can expect 2.4 million euros.

TWENTE UNIVERSITY
P.O. Box 217
7500 AE Enschede
http://www.utwente.nl




Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...